🏛️ Verified NIH Record • Updated 2024-11-14
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer (NCT04294264)
TAS-102 in Combination With Oxaliplatin (TAS-OX) for Refractory Metastatic Colorectal Cancer
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Rutgers, The State University of New Jersey
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Who can join: Review the eligibility criteria below.
Location: Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- Trinitas Hospital and Comprehensive Cancer Center — Elizabeth, New Jersey
- RWJBarnabas Health - Monmouth Medical Center Southern Campus — Lakewood, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- RWJBarnabas Health - Monmouth Medical Center — Long Branch, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- RWJBarnabas Health - Community Medical Center — Toms River, New Jersey
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Colorectal Carcinoma
- Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer — Columbus, Ohio
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer — Phoenix, Arizona
- BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma — Birmingham, Alabama
- M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery — Los Angeles, California
- HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization — Rochester, Minnesota
Explore by condition: All Metastatic Colorectal Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.